Coherus Oncology, Inc. (CHRS)

From the record

Coherus Oncology, Inc.'s filings since 2017 show 3 warning events of 3 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2024-03-04); a notice about its exchange listing (8-K item 3.01, the latest 2025-07-03); an auditor change (8-K item 4.01, the latest 2026-06-15) (its current reports).

From the record

Coherus Oncology, Inc.'s 10 filed years say what it did: revenue went from $189 million in fiscal 2016 to $42 million in fiscal 2025, down 15.4% a year; it rose in 3 of 8 years; the deepest fall was 100% from fiscal 2016 to fiscal 2018; net income was positive in 4 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Coherus Oncology, Inc. earned about 275 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 11 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 76 cents per dollar of assets, and net share issuance: its share count grew 2.3% over the year (the filed statements).

From the record

Coherus Oncology, Inc.'s standing among 102 graded names in its industry family: revenue of $42 million in fiscal 2025 ranks in the top 43% by size; a net margin of 398.4% ranks in the top 1%; revenue growth of -41.5% a year over the last 3 filed years ranks in the bottom 14% (its annual reports).

From the record

Coherus Oncology, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Lanfear, Dennis M (President & CEO, as filed), filing under that title since 2014-11-06, 12 years (top 6% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 4.5 years (bottom 31%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Coherus Oncology, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $89 million against no long-term debt tagged leaves 34.4% of its assets as net cash, top 44% of its family; cash from operations less capital spending is -328.4% of revenue (bottom 43%); a gross margin of 67.2% (bottom 48%); research spending of 258.2% of revenue (top 41%) (its annual report).

From the record

Coherus Oncology, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -41.5% a year over the last three filed years against -15.4% over all 10, slowing (bottom 27% of its family); the newest year grew 59.9% (top 30%); research spending grew -18.3% a year (bottom 15%); capital spending grew -66% a year (bottom 11%) (its annual reports). Coherus Oncology, Inc. reported 2 product lines in fiscal 2025: Toripalimab at $41 million (97%), Product and Service Other at $1 million (3%); 1 of 2 grew against the year before (its annual report).

From the record

Coherus Oncology, Inc.'s newest year against its own record: revenue of $42 million in fiscal 2025 came in 351.6% above the $9 million its prior three years' pace pointed to (top 9% of its family); net income of $168 million against a prior three-year average of $167 million (top 7%); a net margin of more than its whole revenue against -40.9% before (top 26%) (its annual reports).